Table 3 Changes of ADMA concentration in cardiac tissues
From: Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats
Variables | Sham | Control | Low-dose | High-dose |
|---|---|---|---|---|
Pre-medical treatment (8 weeks of model production, n = 5 each group) | ||||
ADMA (μmol/mg protein) | 35.15 ± 6.03* | 48.53 ± 8.08 | 50.44 ± 10.52 | 49.67 ± 7.33 |
Post-medical treatment (4 weeks of medical treatment, n = 10 each group) | ||||
ADMA (μmol/mg protein) | 36.08 ± 7.43* | 51.51 ± 8.26 | 47.26 ± 8.27 | 41.50 ± 7.08# |